Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that nearly 40 company-sponsored and investigator-sponsored investigational studies evaluating carfilzomib, a second-generation proteasome inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in early development, will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the Ernest N. Morial Convention Center in New Orleans, LA.

"We are encouraged by the breadth of data from our Proteasome Inhibitor franchise being presented this year at ASH, which add to the clinical data of carfilzomib in combination with other therapies and provide further insight into the level of response for carfilzomib at a molecular level. Additionally, data to be presented on oprozomib offer clinical insights instrumental in driving forward our clinical development program for the compound," said Pablo Cagnoni, M.D., President of Onyx Pharmaceuticals, Inc.  "We remain committed to bringing innovative therapies to patients in need, and we look forward to playing a continued role in advancing the scientific understanding of hematologic malignancies."

Among the presentations are five abstracts from the Proteasome Research and Integrative Science for Multiple Myeloma – Novel Therapies Program (PRISM NTP), a global research collaboration between Onyx, investigators at myeloma centers of excellence and partner companies with novel therapies in development. "The PRISM program further demonstrates our commitment to innovation and advancing science," said Homa Yeganegi, Vice President of Scientific Affairs a
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Calif. , July 24, 2014 SRI ... contract with the National Institute of Allergy and Infectious ... to conduct preclinical development of potential therapies for HIV ... drugs to treat HIV and AIDS and the complications ... as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... July 24, 2014  Neogen Corporation (Nasdaq: ... of its potential revenue from new rodenticide research are ... and analysts on July 22, 2014, Neogen,s CEO commented ... this research. "It was my intent Tuesday ... potential of a new type of rodenticide, but certainly ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... entrepreneurship http://www.draperuniversity.com , is proud to announce ... entrepreneurs from 17 different countries will converge on ... Silicon Valley for an intensive, experiential program focused ... doing.” The highly selective school, currently running its ...
(Date:7/24/2014)... 24, 2014 The patent provides ... diagnostic test results. It also enables true sample ... validation and reporting of high profile assays such ... a rapidly growing area of biotechnology that includes ... cancer, and companion diagnostics in personalized medicine. The ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3Neogen comments on SenesTech 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3New DNA-barcode Patent Virtually Eliminates False Test Results and Sample Mix-up 2
... Microsoft chairman and chief software architect Bill Gates talked ... industry when he stopped in their classroom during his ... included in the tour, which is promoting greater youth ... Communications. Photo by Jeff Miller , ...
... Wis. - These are not your parents' generation ... "cool" was rarely heard to cross the lips of ... commodity. The problem is that Wisconsin doesn't yet have ... dozen representatives of business, civic, academic and arts groups ...
... Madison, Wis. - The 53 Wisconsin companies that ... Business Innovation Research (SBIR) and Small Business Technology Transfer ... recognized at an upcoming banquet in Madison. , ,The ... technology transfer workshop. The workshop will focus on SBIR/STTR ...
Cached Biology Technology:Gates displays software's future to UW-Madison students 2Gates displays software's future to UW-Madison students 3Gates displays software's future to UW-Madison students 4Tech leaders call for more creativity 2
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... the National Consortium for Data Science (NCDS) aims to ... and data science research, a move that will help ... the data-driven global economy. The consortium, ... University of North Carolina at Chapel Hill, unites data ...
... reveals that age matters when it comes to adapting to ... insight and understanding of the likely impact of predicted environmental ... the journal Global Change Biology scientists from British ... the Alfred Wegener Institute reveal that when it comes to ...
... An international team of researchers has decoded the genome ... and illuminating: the African coelacanth. A sea-cave dwelling, five-foot ... thought to be extinct. A living coelacanth was discovered ... questions about these ancient-looking fish popularly known as ...
Cached Biology News:National consortium to lead North Carolina in big data innovation 2National consortium to lead North Carolina in big data innovation 3Age matters to Antarctic clams 2Coelacanth genome surfaces 2Coelacanth genome surfaces 3Coelacanth genome surfaces 4
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
MAb to Vasopressin Preservative: NaN3...
... α, clone 8G8/5 GenBank Accession Number ... human AP-2alpha/gamma fusion protein corresponding to residues ... of human AP-2γ Formulation: 0.1M Tris-glycine, pH ... the addition of glycerol to 30% Quality ...
Biology Products: